Latest News

Market capUnder $1B
SectorsAll
Filter by sector
Thursday, October 15, 2026· 2250 stock ideas· 217 writers·
15,065 views· 7,193 clicks

From X

@AsifSuria 1 click

Asif Suria on X

Now that the Bumble $BMBL deal is confirmed, the key question is: when will this deal close? Usually we get an indication of that in the press release announcing the deal but that was not the case here. There is also something called the "outside date" that is specified in the merger agreement filed with the SEC and this is the drop dead date by which both parties expect to close the deal. Like most things in life, there are exceptions and outside dates often have extensions. In the case of Bumble, the outside date is July 12, 2027. Ithaca has also indicated that they don't plan to close before November 26, 2026. So we land somewhere between November 26, 2026 and July 12, 2027. The average time it takes deals to close based on about 15 years of our internal data tracking M&A is 120 days. Biotech deals generally tend to close much faster and the average there is closer to 90 days. Considering there doesn't appear to be shareholder, financing or antitrust risk here, I would not be surprised if this one closed in less than 90 days. Personally I would prefer that it close in 2027, so I don't have to think about short-term gains this year. Another situation I was involved in last year (the narcolepsy drug company Avadel), ended up closing just days before it would have turned into a long-term position for me and we ended up paying short-term capital gains on it. This is one of the issues with all cash deals that force a tax event for long-term shareholders.

Free Recaps of the best new stock ideas, delivered every morning.

Namib Minerals: Research Note

Namib Minerals posted H1 adjusted EBITDA of $19.0 million, up 76%, as higher gold prices offset lower production.

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

SRTA · long

Strata Critical Medical INC

Strata Critical Medical, SRTA, supplies organ-transport products tied to U.S. transplant growth.

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

Have a source we’re missing? Send your pick

Recent recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

X accounts we follow

Every account on this site, hand-picked.

88 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick